Approaching the end of the year, Wistar takes stock of its federal funding performance. During the 2020 fiscal year of the National Institutes of Health (NIH) — the U.S. government agency that supp…
A conversation with Anne Schoemaker about her vision to sponsor The Wistar-Schoemaker International Postdoctoral Fellowship, a partnership launched in 2019 by Wistar and Leiden University Medical C…
Wistar’s first Women & Science event of the COVID-19 era took place virtually and, appropriately, featured Dr. Ami Patel, a Wistar scientist that is playing a major role in the work being done …
Dr. Ian Tietjen came to Wistar in 2019 as a research assistant professor in the laboratory of Dr. Luis Montaner. He brings a fascinating approach to HIV and infectious disease research th…
Antiretroviral therapy (ART) has dramatically increased the health and life expectancy of HIV-infected individuals, suppressing virus replication in the host immune cells and stopping disease …
As our state economy faces a long slog back to recovery from the COVID-19 pandemic, Wistar is poised to assist with the development of the workforce that will help enable that recovery. The In…
Creating a new drug from scratch takes many years and billions of dollars. While discovery of new molecules against SARS-CoV-2 and other emerging viruses is imperative, the world also needs solutio…
Dr. Maureen Murphy, Ira Brind Professor and program leader of the Molecular & Cellular Oncogenesis Program of The Wistar Institute Cancer Center, has been investigating the importance of inheri…
The effects of COVID-19 have dramatically changed the way we live, learn and work. While many things have come to a standstill, Wistar research has never stopped and even new educational proje…
Despite an unprecedented volume of research, there are still many unanswered questions on COVID-19, especially regarding the extremely varied clinical course the disease takes, ranging from asympto…
